Search Results

Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 29, 2024.

Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2023.

BioLife Solutions, Inc., a leading supplier of bioproduction tools and services for the cell and gene therapy and broader biopharma markets, announced the introduction of the CryoCase, an addition to its CellSeal product line.

NanoImaging Services and Cube Biotech have announced a partnership agreement to develop a streamlined, cryo-EM enabled gene-to-structure workflow, to ultimately accelerate medicinal chemistry analysis and revolutionize the field of membrane protein research.

Cryo-Cell International, Inc., the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2023.

NKGen Biotech, Inc. announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, will present highlights of the Company’s cryopreserved, autologous, non-genetically modified NK cell therapy product, SNK01 at the 5th International Cell & Gene Therapy China Summit & Exhibition to be held in Nanjing, China, from May 22–24, 2024.

IN8bio, Inc. a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced multiple presentations at the International Society for Cell & Gene Therapy 2024, to be held May 28th to June 1st in Vancouver, Canada.

Aspen Neuroscience will present this week to a global audience of clinicians, regulators, researchers, technologists and industry partners at the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, May 29-June 1.

CytoMed Therapeutics Limited has obtained board approval to launch, subject to certain terms and conditions, a pilot program to isolate and cryo-store peripheral blood mononuclear cells for and as a reward to loyal shareholders of CytoMed on a complimentary basis.